English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Colon cancer is one of the most prevalent gastrointestinal tumors in the world. Although conventional treatments of colon cancer, such as surgery, radiotherapy and chemotherapy have improved, the rate of mortality and recurrence remain at a high level. The development and progression of colon cancer is driven by abnormal expression of oncogenes and tumor suppressors (1). Therefore, it is important to explore new targets to develop therapeutic strategies of colon cancer. Hypoxia is an important factor of microenvironment of most solid tumors (2). Hypoxia-inducible factor 1 (HIF1) is a heterodimeric transcription factor consisted of HIF1α subunit and HIF-1β subunit (3). HIF-1β subunit is constitutively expressed, but HIF-1α subunit is regulated Original Article

ANXA3 is upregulated by hypoxia-inducible factor 1-alpha and promotes colon cancer growth